A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT06327256
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Conditions
- Metastatic Breast CancerMetastatic Gastric AdenocarcinomaEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 582
- Registration Number
- NCT06324357
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
- Conditions
- Diabetic Retinopathy
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 178
- Registration Number
- NCT06321302
- Locations
- 🇺🇸
Associated Retina Consultants, Ltd., Phoenix, Arizona, United States
🇺🇸California Retina Consultants-Bakersfield-65523, Bakersfield, California, United States
🇺🇸Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT06310005
- Locations
- 🇯🇵
Clinical Research Hospital Tokyo, Tokyo, Shinjuku-ku, Japan
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight
- Conditions
- ObesityNon-Alcoholic SteatoHepatitis (NASH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 218
- Registration Number
- NCT06309992
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Gastroenterology and Liver Research LLC, Houston, Texas, United States
🇺🇸Accurate Clinical Research, Inc., Humble, Texas, United States
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 299
- Registration Number
- NCT06287073
- Locations
- 🇰🇷
The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Soonchunhyang University Hospital Seoul, Seoul, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT06280235
- Locations
- 🇨🇳
Hebei Mental Health Center, Baoding, China
🇯🇵Kaku Mental Clinic, Fukuoka-shi, Japan
🇺🇸Excell Research Inc., Oceanside, California, United States
A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems
- Conditions
- HealthyLiver Diseases
- Interventions
- Drug: Avenciguat (BI 685509)
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4
- Registration Number
- NCT06272058
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT06255340
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT06241573
- Locations
- 🇧🇬
ASMC-IPSMC-skin and Veneral Diseases, Sofia, Bulgaria
🇺🇸Clinical Trials Research Institute, Thousand Oaks, California, United States
🇦🇷STAT Research, Caba, Argentina